Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.
Identifieur interne : 002E96 ( Main/Exploration ); précédent : 002E95; suivant : 002E97Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.
Auteurs : Gilles Montalescot [France] ; David Brieger [Australie] ; Anthony J. Dalby [Afrique du Sud] ; Seung-Jung Park [Corée du Sud] ; Roxana Mehran [États-Unis]Source :
- Journal of the American College of Cardiology [ 1558-3597 ] ; 2015.
Descripteurs français
- KwdFr :
- Antagonistes des récepteurs purinergiques P2Y (administration et posologie), Antiagrégants plaquettaires (administration et posologie), Endoprothèses à élution de substances (tendances), Essais contrôlés randomisés comme sujet (tendances), Facteurs temps, Humains, Intervention coronarienne percutanée (tendances), Resténose coronaire (), Resténose coronaire (diagnostic).
- MESH :
- administration et posologie : Antagonistes des récepteurs purinergiques P2Y, Antiagrégants plaquettaires.
- diagnostic : Resténose coronaire.
- tendances : Endoprothèses à élution de substances, Essais contrôlés randomisés comme sujet, Intervention coronarienne percutanée.
- Facteurs temps, Humains, Resténose coronaire.
English descriptors
- KwdEn :
- Coronary Restenosis (diagnosis), Coronary Restenosis (prevention & control), Drug-Eluting Stents (trends), Humans, Percutaneous Coronary Intervention (trends), Platelet Aggregation Inhibitors (administration & dosage), Purinergic P2Y Receptor Antagonists (administration & dosage), Randomized Controlled Trials as Topic (trends), Time Factors.
- MESH :
- chemical , administration & dosage : Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists.
- diagnosis : Coronary Restenosis.
- prevention & control : Coronary Restenosis.
- trends : Drug-Eluting Stents, Percutaneous Coronary Intervention, Randomized Controlled Trials as Topic.
- Humans, Time Factors.
Abstract
The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.
DOI: 10.1016/j.jacc.2015.05.053
PubMed: 26271067
Affiliations:
- Afrique du Sud, Australie, Corée du Sud, France, États-Unis
- Nouvelle-Galles du Sud, Région capitale de Séoul, État de New York, Île-de-France
- Paris, Sydney, Séoul
- Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A92
- to stream PubMed, to step Curation: 002A21
- to stream PubMed, to step Checkpoint: 002A21
- to stream Ncbi, to step Merge: 002935
- to stream Ncbi, to step Curation: 002935
- to stream Ncbi, to step Checkpoint: 002935
- to stream Main, to step Merge: 002E97
- to stream Main, to step Curation: 002E96
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.</title><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="3"><nlm:affiliation>ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Pitié-Salpêtriėre, Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Pitié-Salpêtriėre, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name><affiliation wicri:level="4"><nlm:affiliation>Department of Cardiology, Concord Hospital, University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Cardiology, Concord Hospital, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Dalby, Anthony J" sort="Dalby, Anthony J" uniqKey="Dalby A" first="Anthony J" last="Dalby">Anthony J. Dalby</name><affiliation wicri:level="1"><nlm:affiliation>Milpark Hospital, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Milpark Hospital, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author><author><name sortKey="Park, Seung Jung" sort="Park, Seung Jung" uniqKey="Park S" first="Seung-Jung" last="Park">Seung-Jung Park</name><affiliation wicri:level="3"><nlm:affiliation>Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Mehran, Roxana" sort="Mehran, Roxana" uniqKey="Mehran R" first="Roxana" last="Mehran">Roxana Mehran</name><affiliation wicri:level="2"><nlm:affiliation>Icahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Icahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26271067</idno><idno type="pmid">26271067</idno><idno type="doi">10.1016/j.jacc.2015.05.053</idno><idno type="wicri:Area/PubMed/Corpus">002A92</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A92</idno><idno type="wicri:Area/PubMed/Curation">002A21</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A21</idno><idno type="wicri:Area/PubMed/Checkpoint">002A21</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A21</idno><idno type="wicri:Area/Ncbi/Merge">002935</idno><idno type="wicri:Area/Ncbi/Curation">002935</idno><idno type="wicri:Area/Ncbi/Checkpoint">002935</idno><idno type="wicri:Area/Main/Merge">002E97</idno><idno type="wicri:Area/Main/Curation">002E96</idno><idno type="wicri:Area/Main/Exploration">002E96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.</title><author><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name><affiliation wicri:level="3"><nlm:affiliation>ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Pitié-Salpêtriėre, Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Pitié-Salpêtriėre, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name><affiliation wicri:level="4"><nlm:affiliation>Department of Cardiology, Concord Hospital, University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Cardiology, Concord Hospital, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Dalby, Anthony J" sort="Dalby, Anthony J" uniqKey="Dalby A" first="Anthony J" last="Dalby">Anthony J. Dalby</name><affiliation wicri:level="1"><nlm:affiliation>Milpark Hospital, Johannesburg, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Milpark Hospital, Johannesburg</wicri:regionArea><wicri:noRegion>Johannesburg</wicri:noRegion></affiliation></author><author><name sortKey="Park, Seung Jung" sort="Park, Seung Jung" uniqKey="Park S" first="Seung-Jung" last="Park">Seung-Jung Park</name><affiliation wicri:level="3"><nlm:affiliation>Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Mehran, Roxana" sort="Mehran, Roxana" uniqKey="Mehran R" first="Roxana" last="Mehran">Roxana Mehran</name><affiliation wicri:level="2"><nlm:affiliation>Icahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Icahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of the American College of Cardiology</title><idno type="eISSN">1558-3597</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronary Restenosis (diagnosis)</term><term>Coronary Restenosis (prevention & control)</term><term>Drug-Eluting Stents (trends)</term><term>Humans</term><term>Percutaneous Coronary Intervention (trends)</term><term>Platelet Aggregation Inhibitors (administration & dosage)</term><term>Purinergic P2Y Receptor Antagonists (administration & dosage)</term><term>Randomized Controlled Trials as Topic (trends)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs purinergiques P2Y (administration et posologie)</term><term>Antiagrégants plaquettaires (administration et posologie)</term><term>Endoprothèses à élution de substances (tendances)</term><term>Essais contrôlés randomisés comme sujet (tendances)</term><term>Facteurs temps</term><term>Humains</term><term>Intervention coronarienne percutanée (tendances)</term><term>Resténose coronaire ()</term><term>Resténose coronaire (diagnostic)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Platelet Aggregation Inhibitors</term><term>Purinergic P2Y Receptor Antagonists</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antagonistes des récepteurs purinergiques P2Y</term><term>Antiagrégants plaquettaires</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronary Restenosis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Resténose coronaire</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronary Restenosis</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Endoprothèses à élution de substances</term><term>Essais contrôlés randomisés comme sujet</term><term>Intervention coronarienne percutanée</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug-Eluting Stents</term><term>Percutaneous Coronary Intervention</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs temps</term><term>Humains</term><term>Resténose coronaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated in randomized studies with apparently conflicting results. Although longer exposure associates with more bleeding complications, late stent thrombosis (ST) and myocardial infarction are reduced. In addition, as new drug-eluting stents carry a lower risk of ST compared with the first-generation drug-eluting stents and possibly even bare-metal stents, a shift toward better protection from ST may have an effect on the duration and intensity of DAPT. Whether the duration of DAPT should be shorter or longer than the currently recommended 6 to 12 months is analyzed in this review, drawing on lessons from the most recent studies.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>Australie</li><li>Corée du Sud</li><li>France</li><li>États-Unis</li></country><region><li>Nouvelle-Galles du Sud</li><li>Région capitale de Séoul</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Sydney</li><li>Séoul</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Montalescot, Gilles" sort="Montalescot, Gilles" uniqKey="Montalescot G" first="Gilles" last="Montalescot">Gilles Montalescot</name></region></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Brieger, David" sort="Brieger, David" uniqKey="Brieger D" first="David" last="Brieger">David Brieger</name></region></country><country name="Afrique du Sud"><noRegion><name sortKey="Dalby, Anthony J" sort="Dalby, Anthony J" uniqKey="Dalby A" first="Anthony J" last="Dalby">Anthony J. Dalby</name></noRegion></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Park, Seung Jung" sort="Park, Seung Jung" uniqKey="Park S" first="Seung-Jung" last="Park">Seung-Jung Park</name></region></country><country name="États-Unis"><region name="État de New York"><name sortKey="Mehran, Roxana" sort="Mehran, Roxana" uniqKey="Mehran R" first="Roxana" last="Mehran">Roxana Mehran</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26271067
|texte= Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26271067" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |